Pyxis Oncology releases MICVO clinical update presentation

Pyxis Oncology published a corporate deck detailing an interim clinical update for micvotabart pelidotin (MICVO), an EDB+FN-targeting antibody-drug conjugate.

• In 2L+ recurrent or metastatic HNSCC, the 5.4 mg/kg Q3W dose-capped subgroup showed 36% confirmed ORR and 94% disease control.
• Median progression-free survival was 6.2 months; 12-month overall survival probability was 79% in the dose-capped analysis.
• Management highlighted a Phase 3 start planned for mid-2027; dose capping was adopted to reduce toxicity in higher-weight patients.